Amalgamated Bank’s Aimmune Therapeutics AIMT Stock Holding History

Amalgamated Bank’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-7,231	Closed	-$249K	–	1612
2020 Q3	$249K	Buy	+7,231	New	+$154K	0.01%	1213
2020 Q1	–	Sell	-8,438	Closed	-$282K	–	1826
2019 Q4	$282K	Buy	+8,438	New	+$236K	0.01%	1443

Amalgamated Bank's AIMT Position: Q4 2020 in Review

Amalgamated Bank sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 7,231 shares — an estimated $249K sold.

Amalgamated Bank first reported a position in AIMT in Q4 2019 and held it in 2 quarters. The position peaked at $282K in Q4 2019. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

Amalgamated Bank reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
Amalgamated Bank sold 7,231 Aimmune Therapeutics shares in Q4 2020, an estimated $249K.
Amalgamated Bank first reported a position in Aimmune Therapeutics in Q4 2019 and held it in 2 quarters.
Amalgamated Bank's Aimmune Therapeutics position peaked at $282K in Q4 2019.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Amalgamated Bank's 13F filing for Q4 2020, filed 12 Feb 2021.